Fmoc-Aib-OH in peptide research: what the building block contributes
Where Fmoc-Aib-OH fits in peptide synthesis, how to read a published application, and which reference data belong to the building block.
Published by Talvenca
Aib often appears in a peptide project because the team wants to change a residue, then measure what that change does. The useful starting point is the intended sequence and comparison—not an assumption that adding Aib will improve every peptide.
What is being added to the sequence?
Aib is α-aminoisobutyric acid. Its α-carbon carries two methyl groups. Fmoc-Aib-OH is the amino-protected building block used to introduce an Aib residue during Fmoc solid-phase peptide synthesis (SPPS), as described in the Novabiochem product record.
| Reference field | Value |
|---|---|
| Building block | Fmoc-Aib-OH |
| CAS | 94744-50-0 |
| Molecular formula | C19H19NO4 |
| Approximate molar mass | 325.4 g/mol |
These are identity data for the protected starting material. They are not the molecular mass of a finished peptide, a batch assay or a purity specification.
For project planning, write down the proposed substitution and the question it is meant to answer. A comparison of peptide stability needs a defined stability test; a comparison of receptor binding needs a binding assay. Passing an identity check on the starting material answers neither of those performance questions.
A published application, with the number kept in context
Lau and colleagues' 2015 semaglutide discovery paper describes Aib at position 8, an Arg substitution at position 34 and derivatization at Lys26. It reports a 46.1-hour plasma half-life in mini-pigs after intravenous administration for the complete analogue.
That figure describes a particular molecule and animal study. It does not isolate the contribution of Aib, establish a human half-life, or measure Fmoc-Aib-OH from Talvenca. The example is useful because it shows an Aib residue within a documented peptide design containing several deliberate modifications.
Turn the application into an evaluation plan
For an analogue comparison, agree on the reference sequence and which variables will be held constant. If the linker, conjugation site and residue all change together, the experiment can compare complete designs, but it cannot attribute the result to the residue alone.
Before interpreting a biological result, establish that the peptide samples being compared have the intended identities and an appropriate analytical assessment. Keep the final peptide analysis alongside the starting-material records; they serve different purposes.
The synthesis team should also decide how incorporation will be checked within its existing process. A supplier's general application description is a reason to evaluate the building block, not a validated coupling cycle for every sequence and resin. Record any process changes so a later repeat can follow the same basis.
What information is useful when sourcing it?
Start from Fmoc-Aib-OH, and state the evaluation quantity, required specification and documents needed before use. If you are comparing batches or planning a repeat, include the earlier lot reference. The sample-to-order checklist helps connect that evaluation to a later purchase.
For an initial technical-document request, it is enough to describe the material and the question you need to resolve. A confidential peptide sequence can stay within your team while the identity and documentation requirements are discussed.